Jheelam Banerjee1, Hussein A N Al-Wadei, Hildegard M Schuller. 1. Experimental Oncology Laboratory, Department of Biomedical & Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA.
Abstract
AIM OF STUDY: Smoking is an established risk factor for pancreatic cancer and nicotine replacement therapy (NRT) often accompanies chemotherapy. The current study has tested the hypothesis that chronic exposure to low dose nicotine reduces the responsiveness of pancreatic cancer to the leading therapeutic for this cancer, gemcitabine. METHODS: The effects of chronic nicotine (1 μm/L) on two pancreatic cancer cell lines in vitro and in a xenograft model were assessed by immunoassays, Western blots and cell proliferation assays. RESULTS: Exposure in vitro to nicotine for 7 days inhibited the gemcitabine-induced reduction in viable cells, gemcitabine-induced apoptosis as indicated by reduced expression of cleaved caspase-3 while inducing the phosphorylation of signalling proteins extracellular signal-regulated kinase (ERK), v-akt thymoma viral oncogene homolog (protein kinase B, AKT) and Src. Nicotine (1 μm/L) in the drinking water for 4 weeks significantly reduced the therapeutic response of mouse xenografts to gemcitabine while reducing the induction of cleaved caspase-3 and the inhibition of phosphorylated forms of multiple signalling proteins by gemcitabine in xenograft tissues. CONCLUSIONS: Our experimental data suggest that continued moderate smoking and NRT may negatively impact therapeutic outcomes of gemcitabine on pancreatic cancer and that clinical studies in cancer patients are now warranted.
AIM OF STUDY: Smoking is an established risk factor for pancreatic cancer and nicotine replacement therapy (NRT) often accompanies chemotherapy. The current study has tested the hypothesis that chronic exposure to low dose nicotine reduces the responsiveness of pancreatic cancer to the leading therapeutic for this cancer, gemcitabine. METHODS: The effects of chronic nicotine (1 μm/L) on two pancreatic cancer cell lines in vitro and in a xenograft model were assessed by immunoassays, Western blots and cell proliferation assays. RESULTS: Exposure in vitro to nicotine for 7 days inhibited the gemcitabine-induced reduction in viable cells, gemcitabine-induced apoptosis as indicated by reduced expression of cleaved caspase-3 while inducing the phosphorylation of signalling proteins extracellular signal-regulated kinase (ERK), v-aktthymoma viral oncogene homolog (protein kinase B, AKT) and Src. Nicotine (1 μm/L) in the drinking water for 4 weeks significantly reduced the therapeutic response of mouse xenografts to gemcitabine while reducing the induction of cleaved caspase-3 and the inhibition of phosphorylated forms of multiple signalling proteins by gemcitabine in xenograft tissues. CONCLUSIONS: Our experimental data suggest that continued moderate smoking and NRT may negatively impact therapeutic outcomes of gemcitabine on pancreatic cancer and that clinical studies in cancerpatients are now warranted.
Authors: Vivian Yvonne Shin; William Ka Kei Wu; Kent Man Chu; Marcel Wing Leung Koo; Helen Pui Shan Wong; Emily Kai Yee Lam; Emily Kin Ki Tai; Chi Hin Cho Journal: Toxicol Sci Date: 2006-09-26 Impact factor: 4.849
Authors: Jheelam Banerjee; Hussein An Al-Wadei; Mohammed H Al-Wadei; Koami Dagnon; Hildegard M Schuller Journal: BMC Cancer Date: 2014-09-27 Impact factor: 4.430
Authors: Patrick W Underwood; Dong Yu Zhang; Miles E Cameron; Michael H Gerber; Daniel Delitto; Michael U Maduka; Kyle J Cooper; Song Han; Steven J Hughes; Sarah M Judge; Andrew R Judge; Jose G Trevino Journal: Cancers (Basel) Date: 2020-02-01 Impact factor: 6.639
Authors: M Abd-Elsabour; Hesham M Alsoghier; Abdulrahman G Alhamzani; Mortaga M Abou-Krisha; Tarek A Yousef; Hytham F Assaf Journal: Nanomaterials (Basel) Date: 2022-07-09 Impact factor: 5.719